GHRP-2

GHRP-2 (growth hormone-releasing peptide-2, also referenced in the literature as pralmorelin) is a synthetic hexapeptide secretagogue supplied in lyophilized form for laboratory preparation. It belongs to the broader class of growth hormone secretagogue (GHS) compounds studied alongside ghrelin-mimetic peptides, and it is characterized in research settings by its short amino-acid sequence and its reported activity at the growth hormone secretagogue receptor (GHS-R). This product is offered exclusively as a research chemical and professional reference material for licensed practitioners and qualified laboratory settings; it is not approved by the FDA for therapeutic use, and nothing herein constitutes a therapeutic, diagnostic, or treatment claim. It is provided for research and professional use only.

Within the Growth Hormone and Performance category, GHRP-2 is one of the more frequently referenced secretagogue peptides in the preclinical and investigational literature, where it is often examined in parallel with related GHRPs and growth hormone-releasing hormone (GHRH) analogs. Any reference to observed effects reflects published research contexts only; individual results vary, and applications outside controlled research are outside the scope of this material.

• Studied in preclinical and clinical research literature in relation to endogenous growth hormone (GH) release via the secretagogue pathway, where individual results vary
• Investigated as a research tool for probing the growth hormone secretagogue receptor (GHS-R) and ghrelin-mimetic signaling
• Examined in the literature in relation to GH/IGF-1 axis dynamics and pulsatile GH secretion in research models
• Referenced in investigational work on appetite-regulation and feeding-behavior pathways, where individual results vary
• Explored in combination-peptide research alongside GHRH analogs to characterize potential secretagogue interactions in controlled settings

Reference handling information only: GHRP-2 is typically supplied as a lyophilized powder and reconstituted with bacteriostatic water for laboratory preparation; sterile or bacteriostatic diluent is selected at the discretion of the qualified user. Prior to reconstitution, vials are generally stored frozen or refrigerated and kept sealed, away from light, heat, and humidity. After reconstitution, the solution is commonly kept refrigerated, protected from light, and handled under aseptic conditions; freeze-thaw cycling and prolonged room-temperature exposure are generally avoided to help preserve peptide integrity. Always confirm lot-specific storage guidance on the certificate of analysis. This is reference information for storage and handling only and does not include or imply any usage protocol; all clinical and research protocols, including any dosing, are determined solely by the licensed ordering provider, and this material is not medical advice.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

In the published research literature, GHRP-2 is described as a growth hormone secretagogue reported to act as an agonist at the growth hormone secretagogue receptor (GHS-R1a), the same receptor engaged by the endogenous peptide ghrelin. Engagement of this receptor on the anterior pituitary and within the hypothalamus has been reported in research to be associated with the release of stored growth hormone, an effect that has been characterized as largely distinct from, and potentially complementary to, the GHRH pathway. Some studies also describe a secondary influence on hypothalamic somatostatin tone. Across study models, the reported research observation is an association with increased pulsatile GH output; mechanistic interpretation remains within an investigational framework, and individual results vary.